• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why CVS Health (CVS) Is Up 7.9% After 2027 Medicare Advantage Rate Hike Approval And What's Next

    Simply Wall St·04/11/2026 21:30:42
    Listen to the news
    • Earlier this month, the US government approved higher Medicare Advantage payment rates for 2027, improving revenue visibility for major insurers such as CVS Health’s Aetna unit and reinforcing the role of managed-care plans in the federal program.
    • This policy shift arrives as CVS is reshaping its footprint with pharmacy-only locations and integrated care offerings, potentially amplifying the impact of richer Medicare funding across its insurance, pharmacy, and primary care platforms.
    • Next, we’ll examine how this Medicare Advantage rate increase could reshape CVS Health’s investment narrative, especially its earnings recovery assumptions.

    AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    CVS Health Investment Narrative Recap

    To own CVS Health, you need to believe its integrated model across insurance, pharmacy, and care delivery can translate favorable Medicare funding into more durable margins. The surprise 2027 Medicare Advantage rate increase directly supports the near term earnings recovery catalyst, while persistent medical cost and margin pressure in Health Care Delivery remains the biggest risk. The stock’s sharp move on the CMS news suggests expectations have reset, but the long term margin story is still unproven.

    The most immediately relevant announcement is CVS’s plan to roll out nearly 20 smaller, pharmacy only locations alongside more than 40 new pharmacies in 2026. This format concentrates on prescriptions and pharmacist services, tying closer pharmacy engagement to Aetna’s Medicare Advantage membership and potentially reinforcing CVS’s integrated care thesis at the heart of the current catalyst. At the same time, it sits against a backdrop of reimbursement pressure and structurally weaker front end retail trends that...

    Read the full narrative on CVS Health (it's free!)

    CVS Health's narrative projects $443.4 billion revenue and $10.3 billion earnings by 2029. This requires 3.5% yearly revenue growth and a $8.5 billion earnings increase from $1.8 billion today.

    Uncover how CVS Health's forecasts yield a $96.50 fair value, a 22% upside to its current price.

    Exploring Other Perspectives

    CVS 1-Year Stock Price Chart
    CVS 1-Year Stock Price Chart

    Five members of the Simply Wall St Community see CVS Health’s fair value between US$96.50 and US$273.98, highlighting very different expectations. When you weigh those against the recent Medicare Advantage rate uplift and the ongoing risk of elevated medical benefit ratios, it becomes clear that examining several perspectives can materially change how you think about CVS’s earnings resilience.

    Explore 5 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.